Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06414278 · ClinicalTrials.gov registry record
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- 38
- Enrollment target
- 1
- Study location
NCT06414278: Recruiting study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Masonic Cancer Center, University of Minnesota.
NCT06414278 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 38 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06414278, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates the use of a tool kit, Stress, Affect, Language and Speech Analysis (SALSA), for early identification of cognitive side effects of immunotherapy compared to the standard of care assessment.
Primary Outcome
Descriptive statistics will be used to summarize the feasibility of SALSA in CAR-T patients. The overall completion rate of will be calculated for each patient, as well as the pattern of completions.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Minnesota
- University of Minnesota/Masonic Cancer Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2028-02-21 |
What NCT06414278 shows while recruiting
NCT06414278 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06414278 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06414278 about?
NCT06414278 is a clinical study titled "Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy". This clinical trial evaluates the use of a tool kit, Stress, Affect, Language and Speech Analysis (SALSA), for early identification of cognitive side effects of immunotherapy compared to the standard of care assessment.
What is the current status of trial NCT06414278?
This trial is currently recruiting. The enrollment target is 38 participants. The study started on 2024-02-08. Estimated completion is 2028-02-21.
What conditions does trial NCT06414278 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm.
What interventions are being tested in trial NCT06414278?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06414278?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06414278 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06414278's enrollment target sits among peer trials
38 138th of 176 higher than 38 of 176 other Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
RECRUITING · NA
-
Voices: Messages of Wisdom and Hope in the Face of Illness
RECRUITING
-
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RECRUITING
-
Genetic Testing for the Prevention of Cancer in Indigenous American Communities (JUNIPER Trial)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI